Designing Modern Trials - Part 1: Master Protocols Accommodate Advances

By Derk Arts

Randomized clinical trials (RCTs) have traditionally been considered the gold standard in clinical research. However, various factors such as time constraints, costs, limited patient populations, and ethical barriers can often make it impractical to conduct an RCT. Furthermore, as these studies reach completion and their results are published, the conclusions may already be outdated or irrelevant in the current context.

While RCTs still hold significance within the life sciences space, researchers must learn to adapt the traditional trial design paradigm to keep pace with the ongoing advancements in genomics, immunology, and precision medicine. Learn what teams are doing to stay abreast of these changes and the role master protocols play in impacting fast-moving medical treatment studies.